OGT’s miRNA Profiling Service Provides Answers for Disease Research
News May 16, 2008
Oxford Gene Technology (OGT) has announced the launch of a new microRNA (miRNA) profiling service designed to help researchers accelerate their discoveries.
In developing this service, OGT has co-funded the design of novel miRNA microarrays with the MolPAGE project (Molecular Phenotyping to Accelerate Genomic Epidemiology), a pan European consortium co-ordinated by Oxford University that focuses on diabetes and vascular disease.
According to company, the new microarray will be used to measure the expression levels of mature miRNA and miRNA star sequences (miRNA*) in biomarker discovery samples.
Dr Mike Evans, Chief Executive at OGT said: ”OGT aims to be at the forefront of emerging technology and welcomes the opportunity to network with leading scientists in Europe. Our multi-array methodology allows for up to sixteen samples to be tested per slide, and has been optimized for high specificity, reproducibility, and low inter-array variability. The arrays are suitable for diverse studies in several eukaryotic species.”
Back in 2009, researchers identified a herd of Awassi sheep suffering from "day blindness". As that term implies, these sheep were blind during the day (in bright light) but could see at night, in low-light conditions. After identifying the genetic basis of this blindness, researchers have now successfully used gene therapy to restore their daytime vision.READ MORE
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE